Tumor Mutation Burden Biomarker Emerges In Bristol's '026 Lung Cancer Post Mortem

Bristol says it's too early to make predictions for future immunotherapy regimens based on new tumor mutation burden analysis of the failed Opdivo Checkmate 026 trial aired at the AACR meeting, but the company plans to fully explore this important biomarker.